Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.

ABSTRACT:

Introduction

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in the human population affecting an estimated 8% of the world population, especially those living in areas of past and present malaria endemicity. Decreased G6PD enzymatic activity is associated with drug-induced hemolysis and increased risk of severe neonatal hyperbilirubinemia leading to brain damage. The G6PD gene is on the X chromosome therefore mutations cause enzymatic deficiency in hemizygote males and homozygote females while the majority of heterozygous females have an intermediate activity (between 30-80% of normal) with a large distribution into the range of deficiency and normality. Current G6PD qualitative tests are unable to diagnose G6PD intermediate activities which coul

SUBMITTER: Bancone G 

PROVIDER: S-EPMC5940185 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature